The remaining 18 patients in the anti-GPL-core IgA antibody-positive group and 31 patients in the anti-GPL-core IgA antibody-negative group had pulmonary lesions compatible with NTM or bronchiectasis. The gene discussed is CD79A; the disease is bronchiectasis.